| 摘要 |
An inhalable combination of a synergistically effective amount of a selective PDE4 inhibitor and an anticholinergic agent is disclosed, wherein the selective PDE4 inhibitor is 9-cyclopentyl-5, 6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3, 4-c]-1, 2,4triazolo[4,3-a]pyridine or 9-cyclopentyl-5, 6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazol[3,4-c]-1,2,4-triazolo[4,3-a] pyridine or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the anticholinergic agent is not a tiotropium salt. These combinations are suitable for the treatment of obstructive airways and other inflammatory diseases, particularly the obstructive airways diseases asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases exacerbated by heightened bronchial reflexes, inflammation, bronchial hyper-reactivity and bronchospasm. |
